Molybdenum

Evidence Level
Moderate
1 Clinical Trial
4 Documented Benefits
3/5 Evidence Score

Molybdenum is an essential ultratrace mineral required as a cofactor for four known human metalloenzymes: sulfite oxidase (sulfur amino acid metabolism), xanthine oxidase (purine catabolism and uric acid production), aldehyde oxidase (drug/xenobiotic metabolism), and mARC (mitochondrial amidoxime reducing component, involved in nitrogen metabolism). Molybdenum deficiency is extremely rare under normal dietary conditions — the mineral is widely distributed in legumes, grains, and leafy vegetables. It appears in multivitamin formulas primarily for completeness.

Studied Dose 45 mcg/day (RDA for adults); tolerable upper intake level: 2,000 mcg (2 mg)/day; most dietary intakes easily meet RDA; supplemental doses typically 50–150 mcg/day
Active Compound Sodium molybdate or ammonium molybdate — molybdenum bisglycinate chelate for enhanced absorption; extremely small amounts required (mcg/day, not mg/day)

Sulfite detoxification via sulfite oxidase

Sulfite oxidase — the most critical molybdenum enzyme — converts sulfite (SO₃²⁻) to sulfate (SO₄²⁻), preventing sulfite accumulation. Sulfite is produced during the metabolism of sulfur-containing amino acids (methionine, cysteine) and is found in wine and dried fruits as a preservative. Molybdenum deficiency impairs sulfite detoxification, causing sulfite sensitivity symptoms.

Uric acid production via xanthine oxidase

Xanthine oxidase catalyzes the final two steps of purine catabolism — converting hypoxanthine to xanthine and xanthine to uric acid. This molybdenum-dependent enzyme is the target of allopurinol (gout medication) and is essential for normal purine metabolism. Molybdenum adequacy ensures proper purine catabolism and uric acid clearance.

Xenobiotic and drug metabolism via aldehyde oxidase

Aldehyde oxidase metabolizes numerous endogenous aldehydes, drugs, and environmental chemicals — including retinaldehyde (vitamin A metabolism), benzaldehyde, and several pharmaceutical compounds (zaleplon, ziprasidone, methotrexate). Adequate molybdenum is required for normal drug metabolism, particularly relevant for individuals on aldehyde oxidase-metabolized medications.

Essential completeness in multivitamin formulas

While standalone molybdenum supplementation is rarely indicated, its inclusion in comprehensive multivitamin-mineral formulas ensures complete coverage of all essential micronutrients — particularly relevant for individuals with restricted diets, malabsorption conditions, or low legume/grain intake.

1

Molybdenum cofactor (Moco) biosynthesis

Dietary molybdate is incorporated into molybdenum cofactor (Moco) — a tricyclic pyranopterin compound that binds molybdenum and is inserted into all four molybdoenzymes. Moco synthesis is a multi-step pathway conserved across all organisms, and genetic defects in Moco synthesis cause molybdenum cofactor deficiency — a severe inherited metabolic disorder.

2

Oxidative hydroxylation catalysis

Molybdoenzymes catalyze oxidative hydroxylation reactions using water as the oxygen donor — distinct from cytochrome P450 oxidases that use molecular oxygen. This unique reaction mechanism explains the specific substrate profiles of xanthine oxidase and aldehyde oxidase in purine and xenobiotic metabolism.

3

Sulfite oxidase and sulfur amino acid catabolism

Sulfite oxidase in the mitochondrial intermembrane space oxidizes sulfite to sulfate — the terminal step in cysteine and methionine catabolism. Sulfate is then exported for sulfation reactions (glycosaminoglycan synthesis, steroid hormone conjugation) or renal excretion. Without functional sulfite oxidase, sulfite accumulates causing neurological damage.

1
Molybdenum Deficiency in Total Parenteral Nutrition
PubMed

Clinical case series describing molybdenum deficiency in patients receiving prolonged total parenteral nutrition (TPN) without molybdenum supplementation.

Patients receiving long-term TPN without molybdenum.

Molybdenum-deficient TPN patients developed hypermethioninemia, low serum uric acid, elevated sulfite excretion, and neurological symptoms — reversed completely by molybdenum supplementation. Established molybdenum as essential for human health and led to its inclusion in TPN formulas.

Common Potential side effects

Extremely well tolerated at dietary and standard supplemental doses (50–150 mcg/day)
High-dose molybdenum (>10 mg/day) can cause gout-like symptoms by increasing xanthine oxidase activity and uric acid production
Very high doses may impair copper absorption — unlikely at normal supplemental doses

Important Drug interactions

Allopurinol — both inhibit xanthine oxidase; theoretical additive effect on uric acid reduction at very high molybdenum doses
Copper — high molybdenum may reduce copper absorption via competitive mechanisms; monitor copper status with very high molybdenum intake
Aldehyde oxidase-metabolized drugs — molybdenum status affects aldehyde oxidase activity; potential influence on drug metabolism at extreme deficiency or excess